Journal of Clinical Oncology
Articles in this Issue
Pregnancy and infant outcomes post–CD19-directed CAR-T therapy: Tisagenlecleucel (tisa-cel) and/or huCAR19 (CTL119).
7029 Background: Data on pregnancy post–CD19-directed CAR-T therapy for B-cell malignancies are limited (Ligon et al). There is a theoretical risk of cros...
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
TPS8660 Background: NaPi2b, encoded by SLC34A2, is a sodium-dependent phosphate transporter overexpressed in various cancers, particularly high levels in...
Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors.
9551 Background: Patients with advanced melanoma who progress on PD-1 and CTLA-4 inhibitors (IO-R/R) have poor prognosis. Gotistobart is a pH-sensitive an...
Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions.
8643 Background: Taletrectinib is a highly potent, next-generation, central nervous system–active, selective ROS1 tyrosine kinase inhibitor (TKI) that was...
Neuro-oncology anywhere: Preliminary results from a decentralized clinical trial aimed at improving neurocognitive outcomes in patients with CNS malignancy.
e13891 Background: Most patients with central nervous system (CNS) malignancy develop cognitive impairment, fatigue, and mood-related symptoms that are im...
Novel risk factors predictive of anti-PD1 immune checkpoint inhibitor-associated pulmonary toxicity.
e14592 Background: Anti-PD1 Immune checkpoint inhibitors (ICI) are widely used as an effective treatment for many cancers. The most important problem that...
Outcomes of ipilimumab plus nivolumab in metastatic merkel cell carcinoma: A systematic review and meta-analysis.
e21586 Background: Merkel Cell Carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer characterized by high recurrence rates and poor surviva...
Cancer survivorship in Brazil from providers' perspectives.
e13860 Background: Previous research highlights the need to create culturally tailored strategies for comprehensive survivorship care in Brazil. Prelimina...
Redefining criteria for omitting axillary surgery following neoadjuvant systemic therapy in patients with breast cancer.
e12579 Background: Historically considered an indispensable part of the breast cancer treatment, axillary surgery is now increasingly omitted when it does...
Characteristics, risk factors, and mortality of stroke in polycythemia vera: A single-center cohort study from Qatar.
e18591 Background: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with a heightened risk of thrombotic events, including stroke. This...
Tebentafusp in metastatic uveal melanoma patients: Results of the Italian expanded access program.
e21533 Background: Tebentafusp has become a standard of care for metastatic uveal melanoma patients positive for HLA-A*02:01 after the results of the phas...
Incidence and risk factors for venous thromboembolism after CAR T-cell therapy: A systematic review and meta-analysis.
e24085 Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematologic cancer treatment; however, the incidence of venous thromb...
Global inequities in sarcoma clinical trials: A comprehensive analysis over the last decade.
11575 Background: Sarcomas are rare, comprising 15% of childhood cancers and 1% of adult cancers, yet survival rates remain poor. The overall 5-year survi...
Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation.
6511 Background: Post-transplant cyclophosphamide (PTCy) at 50 mg/kg on D+3 & +4 after allogeneic hematopoietic cell transplantation (HCT) is establis...
Validation of the International Consensus Classification (ICC) for systemic mastocytosis and the Mayo Alliance Prognostic Score (MAPS) in 910 consecutive patients.
e18596 Background: The International Consensus (ICC), but not the 5 th edition of the WHO classification (WHO5), distinguishes mat...
Personalized survival prediction in primary urinary tract melanoma (PMUT) using a nomogram.
e21550 Background: PMUT is an extremely rare subtype of mucosal melanoma that accounts for 1% of all melanomas. A prognostic index for estimating the clin...
Understanding access to novel high-cost therapies across Canada: A survey of pediatric oncology providers.
e13500 Background: In Canada’s publicly funded healthcare system, access to novel cancer therapies is often inequitable. Despite compelling evidence for t...
Transforming care: Direct pathologist-patient interactions.
e13564 Background: Since 2021, the 21 st Century Cures Act has required near-immediate release of test results to patient portals,...
Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.
5065 Background: Phase III studies of dual therapy with an androgen receptor (AR) antagonist, apalutamide (Apa) or enzalutamide (Enza) with abiraterone ac...
A clinical and genomic landscape analysis of GI stromal tumors.
11512 Background: Gastrointestinal stromal tumors (GIST) are malignant mesenchymal tumors with distinct histogenesis and behavior from other sarcomas. Tre...
Implementing a retrieval-augmented generation-based large language model to guide oncologists in searching for FDA-approved therapies for patient treatment planning.
e13612 Background: Identifying targetable genomic alterations to guide treatment options is a key component of personalized cancer care. However, staying...
Utility of the PROSTest, a novel blood-based molecular assay, versus PSA for prostate cancer stratification and detection of higher grade disease.
5107 Background: Prostate cancer (PCa) is the most common solid organ cancer in men and the fifth leading cause of cancer-related deaths globally. PSA has...
Neoadjuvant ONO-4578, an EP4 antagonist, in combination with nivolumab after chemoradiation therapy in locally advanced resectable rectal cancer.
3588 Background: Neoadjuvant nivolumab (NIV) after preoperative chemoradiation therapy (CRT) demonstrated promising pathologic complete response (pCR) in...
Randomized trial of a clinical nurse specialist–led enhanced survivorship and early palliative care intervention for patients with metastatic cancer.
TPS12139 Background: While the benefits of early palliative care and clinician empathy for patients with metastatic cancer are well established, cancer su...
Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.
8604 Background: NSCLC patients with EGFR mutations develop resistance when treated with EGFR TKI. We previously reported that osimertinib combined with T...